Vimarsana
Biggest News Aggregation in the World

Page 6 - Nasdaq Bcli News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Bcli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Bcli Today - Breaking & Trending Today

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Cut to Sell at StockNews.com - Vimarsana News

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Cut to Sell at StockNews.com

StockNews.com lowered shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Sunday morning. Brainstorm Cell Therapeutics Stock Performance Shares of NASDAQ BCLI opened at $1.84 on Friday. The firm has a market cap of $67.23 million, a price-to-earnings ratio […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.com - Vimarsana News

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock. Shares of BCLI stock opened at $3.02 on Tuesday. The stock has a market cap of $110.19 million, a P/E […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI) & Molecular Partners (NASDAQ:MOLN) Head-To-Head Survey - Vimarsana News

Brainstorm Cell Therapeutics (NASDAQ:BCLI) & Molecular Partners (NASDAQ:MOLN) Head-To-Head Survey

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) and Molecular Partners (NASDAQ:MOLN – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk. Insider & Institutional Ownership 12.3% of Brainstorm Cell […]

Brainstorm Cell Therapeutics (NASDAQ:BCLI) vs. MiNK Therapeutics (NASDAQ:INKT) Head-To-Head Survey - Vimarsana News

Brainstorm Cell Therapeutics (NASDAQ:BCLI) vs. MiNK Therapeutics (NASDAQ:INKT) Head-To-Head Survey

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Profitability This table compares Brainstorm Cell Therapeutics and […]

Zacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Will Announce Earnings of -$0.13 Per Share - Vimarsana News

Zacks: Brokerages Anticipate Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Will Announce Earnings of -$0.13 Per Share

Equities analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) to announce earnings of ($0.13) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics posted earnings of ($0.19) per share during the same quarter last year, which would […]